VcMMAE
Based on 97 publication(s) in Google Scholar
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Assay : 100.7%
- CAS No.: 646502-53-6
- Formule: C68H105N11O15
- Masse moléculaire:1316.63
-
Stockage:
-20°C, sealed storage, away from moisture and light
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-13631E
DeruxtecanDrug-Linker Conjugates for ADC -
HY-15578
McMMAFADC Drug-Linker -
HY-19792
MertansineMicrotubule-Targeted Cytotoxin -
HY-15162
Monomethyl auristatin EAntimitotic Agent -
HY-13631D
DXdTopoisomerase I Inhibitor -
HY-128946
CL2A-SN-38DNA Topoisomerase I Inhibitor -
HY-15575G
VcMMAE (GMP)Drug-Linker Conjugate for ADC -
HY-W011500
TCEP hydrochlorideNon-Thiol Reducing Agent -
HY-112786
MC-Val-Cit-PAB-MMAFDrug-Linker Conjugate for ADC -
HY-100374
Val-Cit-PAB-MMAEDrug-Linker Conjugate For ADC -
HY-B0215
AcetylcysteineMucolytic Agent -
HY-101070
SMCC-DM1Drug-Linker Conjugate for ADC
Publications Citing Use of MedChemExpress (MCE) VcMMAE
More- Signal Transduct Target Ther. 2025 Sep 24;10(1):316. [Abstract]
- Nature. 2024 Apr;628(8007):416-423. [Abstract]
- Nat Commun. 2025 Aug 23;16(1):7889. [Abstract]
- Sci Transl Med. 2025 Jun 18;17(803):eadr4058. [Abstract]
- J Biomed Sci. 2021 Oct 11;28(1):69. [Abstract]
- Adv Sci (Weinh). 2025 Sep 29:e11349. [Abstract]
- Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]
- Sci Adv. 2026 Jan 2;12(1):eady0041. [Abstract]
- J Control Release. 2025 Aug 10:384:113876. [Abstract]
- Cell Death Dis. 2026 Jan 24;17(1):162. [Abstract]
- Cancer Lett. 2026 Jun 28:648:218463. [Abstract]
- Cancer Lett. 2026 Feb 28:639:218225. [Abstract]
- Cancer Lett. 2025 Jun 28:620:217685. [Abstract]
- Cancer Lett. 2025 Feb 28:611:217453. [Abstract]
- J Immunother Cancer. 2024 Oct 2;12(10):e009710. [Abstract]
- Mol Ther. 2025 Dec 2:S1525-0016(25)00959-1. [Abstract]
- J Pharm Anal. 2025 May;15(5):101100. [Abstract]
- Mater Today Bio. 2025 Dec 19.
- Clin Cancer Res. 2021 Jun 1;27(11):3224-3233. [Abstract]
- Acta Pharmacol Sin. 2026 Jan 27. [Abstract]
- J Transl Med. 2025 Nov 20;23(1):1323. [Abstract]
- Int J Biol Macromol. 2024 Jan;254(Pt 1):127657. [Abstract]
- Int J Biol Macromol. 2022 Oct 1:218:243-258. [Abstract]
- Mol Med. 2021 May 7;27(1):46. [Abstract]
- MAbs. 2026 Dec 31;18(1):2663639. [Abstract]
- MAbs. 2025 Dec;17(1):2490078. [Abstract]
- MAbs. 2020 Jan-Dec;12(1):1702262. [Abstract]
- MAbs. 2019 Jan;11(1):153-165. [Abstract]
- J Med Chem. 2025 Jul 10;68(13):13872-13886. [Abstract]
- Cancer Cell Int. 2022 Dec 27;22(1):417. [Abstract]
- Pharmaceutics. 2026 Feb 9;18(2):217. [Abstract]
- Mol Cancer Ther. 2025 Jul 16. [Abstract]
- Pharmaceutics. 2024 Jun 2;16(6):752. [Abstract]
- Mol Cancer Ther. 2023 Apr 3;22(4):459-470. [Abstract]
- Biomater Sci. 2020 Jul 21;8(14):3935-3943. [Abstract]
- Biomacromolecules. 2021 Dec 13;22(12):5349-5362. [Abstract]
- Biomacromolecules. 2021 Oct 11;22(10):4169-4180. [Abstract]
- Mol Cancer Res. 2017 Aug;15(8):1040-1050. [Abstract]
- Pharmaceuticals (Basel). 2024 Jul 16;17(7):949. [Abstract]
- ACS Omega. 2025 Aug 27;10(35):39912-39922. [Abstract]
- ACS Omega. 2017 Jul 31;2(7):3792-3805. [Abstract]
- Mol Ther Methods Clin Dev. 2025 Apr 19;33(2):101476. [Abstract]
- Mol Pharm. 2026 May 21. [Abstract]
- Cancer Sci. 2024 Dec;115(12):3986-3996. [Abstract]
- Mol Pharm. 2022 May 2;19(5):1422-1433. [Abstract]
- Mol Pharm. 2019 Aug 5;16(8):3588-3599. [Abstract]
- Antib Ther. 2026 Mar 12.
- Cancers (Basel). 2020 Oct 15;12(10):2992. [Abstract]
- Bioconjug Chem. 2025 Jun 18;36(6):1288-1298. [Abstract]
- Bioconjug Chem. 2023 Sep 20;34(9):1585-1595. [Abstract]
- Bioconjug Chem. 2016 May 18;27(5):1324-31. [Abstract]
- Bioconjug Chem. 2015 Sep 16;26(9):1923-30. [Abstract]
- Bioconjug Chem. 2015 Jun 17;26(6):1032-40. [Abstract]
- Cancer Res Commun. 2025 Dec 10. [Abstract]
- J Pharm Sci. 2024 Aug;113(8):2433-2442. [Abstract]
- J Pharm Sci. 2024 May;113(5):1265-1274. [Abstract]
- Exp Biol Med (Maywood). 2017 Aug;242(14):1405-1411. [Abstract]
- Cancer Med. 2017 Apr;6(4):798-808. [Abstract]
- Exp Dermatol. 2025 Sep;34(9):e70164. [Abstract]
- J Pharm Biomed Anal. 2024 Sep 15:248:116318. [Abstract]
- Exp Dermatol. 2024 Mar;33(3):e15049. [Abstract]
- PLoS One. 2020 Sep 28;15(9):e0239813. [Abstract]
- Prostate. 2025 Sep;85(13):1208-1221. [Abstract]
- Mol Cell Oncol. 2024 Sep 5;11(1):2399379. [Abstract]
- bioRxiv. 2026 May 27.
- Res Sq. 2026 Apr 24:rs.3.rs-9194287. [Abstract]
- Biomed Pharmacother. 2026 Feb:195:119016. [Abstract]
- SSRN. 2025 Oct 28.
- Patent. US20250277028A1.
- Biomed Pharmacother. 2025 Sep 23:192:118573. [Abstract]
- SSRN. 2025 Aug 6.
- Patent. US20250163175A1.
- bioRxiv. 2025 April 09.
- bioRxiv. 2025 April 07.
- Patent. US20250075182A1.
- Patent. USRE50282.
- Brno University of Technology. 2024.
- SSRN. 2024 Nov 5.
- Patent. US20240261424A1.
- Patent. US20240226318A1.
- Patent. US20240226318A1.
- University of Padova. 2024 Mar.
- bioRxiv. 2024 Feb 23.
- Patent. US20230084099A1.
- Patent. US20220280663A1.
- Patent. US20220249688A1.
- Patent. US20210008222A1.
- Biotechnol Rep (Amst). 2020 Sep 22:28:e00533. [Abstract]
- bioRxiv. 2020 Jun.
- Patent. US20200085969A1.
- Patent. US20190328911A1
- Patent. US10087260B2.
- Patent. US20180200384A1.
- Patent. US20180141976A1
- Kyoto University. 2018 Jan.
- Patent. US20160304621A1.
- Case Western Reserve University. 2016 May.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
Voir tous les produits spécifiques à Isoform Drug-Linker Conjugates for ADC
More
Activité biologique
Description
IC50 & Target
|
Auristatin |
In Vitro
Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[1]. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 646502-53-6
-
Appearance Solid
-
Masse moléculaire 1316.63
-
Formule C68H105N11O15
-
Color White to light yellow
-
SMILES
CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(NC1=CC=C(COC(N(C)[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N2[C@@]([C@H](OC)[C@@H](C)C(N[C@H](C)[C@@H](O)C3=CC=CC=C3)=O)([H])CCC2)=O)C)=O)=O)=O)C=C1)=O)=O)NC(CCCCCN4C(C=CC4=O)=O)=O
-
Synonyms
MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture and light
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (97)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
An aptamer-drug conjugate for promising cancer therapy with comprehensive evaluation from rodents to non-human primates. [Abstract]2025 Sep 24;10(1):316. PMID: 40987771 -
Nature
2024 Apr;628(8007):416-423. PMID: 38538786 -
Nat Commun
2025 Aug 23;16(1):7889. PMID: 40849430 -
Sci Transl Med
Adoptive cell therapy with macrophage-drug conjugates facilitates cytotoxic drug transfer and immune activation in glioblastoma models. [Abstract]2025 Jun 18;17(803):eadr4058. PMID: 40531966 -
J Biomed Sci
Modular self-assembly system for development of oligomeric, highly internalizing and potent cytotoxic conjugates targeting fibroblast growth factor receptors. [Abstract]2021 Oct 11;28(1):69. PMID: 34635096 -
Adv Sci (Weinh)
2025 Sep 29:e11349. PMID: 41024351 -
Cell Rep Med
A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. [Abstract]2026 Apr 21;7(4):102688. PMID: 41856115 -
Sci Adv
Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer. [Abstract]2026 Jan 2;12(1):eady0041. PMID: 41477868 -
J Control Release
Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas. [Abstract]2025 Aug 10:384:113876. PMID: 40409372 -
Cell Death Dis
Preclinical profiling of antibody drug conjugates targeting oncofetal chondroitin sulfate. [Abstract]2026 Jan 24;17(1):162. PMID: 41580438 -
Cancer Lett
A heavy-chain antibody-drug conjugate targeting glycosylated CEACAM6 inhibits brain metastatic tumor growth. [Abstract]2026 Jun 28:648:218463. PMID: 41912133 -
Cancer Lett
2026 Feb 28:639:218225. PMID: 41423054 -
Cancer Lett
A high-affinity antibody-drug conjugates Actuximab-MMAE for potent and selective targeting of CEACAM5-Positive tumors. [Abstract]2025 Jun 28:620:217685. PMID: 40158720 -
Cancer Lett
Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells. [Abstract]2025 Feb 28:611:217453. PMID: 39798832 -
J Immunother Cancer
Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses. [Abstract]2024 Oct 2;12(10):e009710. PMID: 39357981 -
Mol Ther
Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy. [Abstract]2025 Dec 2:S1525-0016(25)00959-1. PMID: 41338184 -
J Pharm Anal
Synergistic approach to combating triple-negative breast cancer: DDR1-targeted antibody-drug conjugate combined with pembrolizumab. [Abstract]2025 May;15(5):101100. PMID: 40521369 -
-
Clin Cancer Res
2021 Jun 1;27(11):3224-3233. PMID: 34074654 -
Acta Pharmacol Sin
Human germline-like monoclonal antibody against 5T4 enables potent ADC and CAR-T therapies for solid tumors. [Abstract]2026 Jan 27. PMID: 41593208 -
J Transl Med
De novo design of a two-step approach targeting Claudin-6 for enhanced drug delivery to solid tumors. [Abstract]2025 Nov 20;23(1):1323. PMID: 41267074 -
Int J Biol Macromol
Targeting HER2 and FGFR-positive cancer cells with a bispecific cytotoxic conjugate combining anti-HER2 Affibody and FGF2. [Abstract]2024 Jan;254(Pt 1):127657. PMID: 38287563 -
Int J Biol Macromol
2022 Oct 1:218:243-258. PMID: 35878661 -
Mol Med
The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells. [Abstract]2021 May 7;27(1):46. PMID: 33962559 -
MAbs
Targeting IL-7Rα with PNU-159682 antibody-drug conjugates in acute lymphoblastic leukemia: translational implications. [Abstract]2026 Dec 31;18(1):2663639. PMID: 42046337 -
MAbs
Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate. [Abstract]2025 Dec;17(1):2490078. PMID: 40202784 -
MAbs
Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly. [Abstract]2020 Jan-Dec;12(1):1702262. PMID: 31876436 -
MAbs
Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models. [Abstract]2019 Jan;11(1):153-165. PMID: 30365359 -
J Med Chem
Innately Fluorescent Tetravalent Cytotoxic Conjugate TetraFHER2-vcMMAE Engages Aggregation-Dependent Endocytosis of HER2 for Enhanced Intracellular Drug Delivery. [Abstract]2025 Jul 10;68(13):13872-13886. PMID: 40581863 -
Cancer Cell Int
Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model. [Abstract]2022 Dec 27;22(1):417. PMID: 36572921 -
Pharmaceutics
CD25-Targeted Aptamer-Drug Conjugate for the Treatment of CD25-Expressing Hematological Malignancies. [Abstract]2026 Feb 9;18(2):217. PMID: 41754959 -
Mol Cancer Ther
The recycling collagen receptor uPARAP is a unique mediator of stromal drug delivery to carcinoma cells. [Abstract]2025 Jul 16. PMID: 40665797 -
Pharmaceutics
Surface-Available HER2 Levels Alone Are Not Indicative of Cell Response to HER2-Targeted Antibody-Drug Conjugate Therapies. [Abstract]2024 Jun 2;16(6):752. PMID: 38931874 -
Mol Cancer Ther
Payload-binding Fab fragments increase the therapeutic index of MMAE antibody-drug conjugates. [Abstract]2023 Apr 3;22(4):459-470. PMID: 36723609 -
Biomater Sci
Affinity of plant viral nanoparticle potato virus X (PVX) towards malignant B cells enables cancer drug delivery. [Abstract]2020 Jul 21;8(14):3935-3943. PMID: 32662788 -
Biomacromolecules
Intrinsically Fluorescent Oligomeric Cytotoxic Conjugates Toxic for FGFR1-Overproducing Cancers. [Abstract]2021 Dec 13;22(12):5349-5362. PMID: 34855396 -
Biomacromolecules
Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model. [Abstract]2021 Oct 11;22(10):4169-4180. PMID: 34542998 -
Mol Cancer Res
High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer. [Abstract]2017 Aug;15(8):1040-1050. PMID: 28483948 -
Pharmaceuticals (Basel)
2024 Jul 16;17(7):949. PMID: 39065798 -
ACS Omega
Characterization of Synthesized Ramucirumab-vcMMAE as a Potential Therapeutic Approach in Ovarian Cancer. [Abstract]2025 Aug 27;10(35):39912-39922. PMID: 40949250 -
ACS Omega
Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors. [Abstract]2017 Jul 31;2(7):3792-3805. PMID: 30023704 -
Mol Ther Methods Clin Dev
Harnessing synaptic vesicle release and recycling with antibody shuttle for targeted delivery of therapeutics to neurons. [Abstract]2025 Apr 19;33(2):101476. PMID: 40454418 -
Mol Pharm
Properties of Drug Linkers Affecting Hydrophobic Interaction Chromatography for Determining the Drug-to-Antibody Ratio of Antibody-Drug Conjugates. [Abstract]2026 May 21. PMID: 42166563 -
Cancer Sci
Anti-tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models. [Abstract]2024 Dec;115(12):3986-3996. PMID: 39322584 -
Mol Pharm
Drug Conjugation via Maleimide-Thiol Chemistry Does Not Affect Targeting Properties of Cysteine-Containing Anti-FGFR1 Peptibodies. [Abstract]2022 May 2;19(5):1422-1433. PMID: 35389227 -
Mol Pharm
Novel Method for Preparation of Site-Specific, Stoichiometric-Controlled Dual Warhead Conjugate of FGF2 via Dimerization Employing Sortase A-Mediated Ligation. [Abstract]2019 Aug 5;16(8):3588-3599. PMID: 31244217 -
-
Cancers (Basel)
FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1. [Abstract]2020 Oct 15;12(10):2992. PMID: 33076489 -
Bioconjug Chem
Transferrin Receptor-Targeted Aptamer-Drug Conjugate Overcomes Blood-Brain Barrier for Potent Glioblastoma Therapy. [Abstract]2025 Jun 18;36(6):1288-1298. PMID: 40359342 -
Bioconjug Chem
2023 Sep 20;34(9):1585-1595. PMID: 37615599 -
Bioconjug Chem
One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies. [Abstract]2016 May 18;27(5):1324-31. PMID: 27074832 -
Bioconjug Chem
Specific Targeting of Proerythroblasts and Erythroleukemic Cells by the VP1u Region of Parvovirus B19. [Abstract]2015 Sep 16;26(9):1923-30. PMID: 26240997 -
Bioconjug Chem
Identification of highly reactive cysteine residues at less exposed positions in the Fab constant region for site-specific conjugation. [Abstract]2015 Jun 17;26(6):1032-40. PMID: 25978737 -
Cancer Res Commun
Targeting uPARAP with an antibody-drug conjugate exhibits efficacy against mesothelioma and synergizes with cisplatin. [Abstract]2025 Dec 10. PMID: 41366685 -
J Pharm Sci
"Negative" Impact: The Role of Payload Charge in the Physicochemical Stability of Auristatin Antibody-Drug Conjugates. [Abstract]2024 Aug;113(8):2433-2442. PMID: 38679233 -
J Pharm Sci
Agitation-Induced Aggregation of Lysine- and Interchain Cysteine-Linked Antibody-Drug Conjugates. [Abstract]2024 May;113(5):1265-1274. PMID: 38070776 -
Exp Biol Med (Maywood)
Featured Article: Delivery of chemotherapeutic vcMMAE using tobacco mosaic virus nanoparticles. [Abstract]2017 Aug;242(14):1405-1411. PMID: 28675044
VcMMAE purchased from MedChemExpress. Usage Cited in: Exp Biol Med (Maywood). 2017 Aug;242(14):1405-1411. [Abstract]
Cell viability assay. Alamar Blue cell viability assay of Karpas 299 cells after 72 hours of treatment with vcMMAE (purple) and TMV-vcMMAE (blue) at 0.02 nM to 200 nM vcMMAE; non-conjugated TMV is also tested using the protein concentration corresponding to the highest vcMMAE dose (200 nM), toxicity of TMV is not observed.
-
Cancer Med
Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen. [Abstract]2017 Apr;6(4):798-808. PMID: 28211613 -
Exp Dermatol
Targeting Melanoma Cell Adhesion Molecule as a Novel Therapeutic Approach for Acral Melanoma. [Abstract]2025 Sep;34(9):e70164. PMID: 40898663 -
J Pharm Biomed Anal
Development and validation of bioanalytical assays for the quantification of 9MW2821, a nectin-4-targeting antibody-drug conjugate. [Abstract]2024 Sep 15:248:116318. PMID: 38908237 -
Exp Dermatol
NECTIN4-targeted antibody-drug conjugate is a potential therapeutic option for extramammary Paget disease. [Abstract]2024 Mar;33(3):e15049. PMID: 38509717 -
PLoS One
Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells. [Abstract]2020 Sep 28;15(9):e0239813. PMID: 32986768 -
Prostate
Annexin A1-Targeted d-Peptide-Monomethyl Auristatin E Conjugate Enhanced Antitumor Effect of Monomethyl Auristatin E for Chemotherapy of Prostate Cancer. [Abstract]2025 Sep;85(13):1208-1221. PMID: 40619855 -
Mol Cell Oncol
An antibody-drug conjugate for endometrioid carcinoma based on the expression of cell adhesion molecule 1. [Abstract]2024 Sep 5;11(1):2399379. PMID: 39252827 -
-
Res Sq
Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties. [Abstract]2026 Apr 24:rs.3.rs-9194287. PMID: 42078873 -
Biomed Pharmacother
Biomimetic bispecific antibody-drug conjugates based on albumin binding domain fusing nanobodies targeting EGFR and HER2. [Abstract]2026 Feb:195:119016. PMID: 41592520 -
-
-
Biomed Pharmacother
Precision targeting of CXCR4+ leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model. [Abstract]2025 Sep 23:192:118573. PMID: 40991987 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Biotechnol Rep (Amst)
Cetuximab produced from a goat mammary gland expression system is equally efficacious as innovator cetuximab in animal cancer models. [Abstract]2020 Sep 22:28:e00533. PMID: 33024714 -
-
-
-
-
-
-
-
-
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (75.95 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 50 mg/mL (37.98 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (1.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: 2.5 mg/mL (1.90 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Cell Assay[2]
Monomethyl auristatin E (MMAE, 5 nM) and ionizing radiation (IR) treated cells are harvested and lysed in RIPA buffer with protease and phosphatase inhibitors. 30μg of lysate undergo electrophoresis using 4-12% Bis-Tris gels, transferred to PVDF membranes and incubated with indicated primary antibodies. Blots are developed by ECL.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration[2]
6-8 week old female athymic nu/nu mice are injected subcutaneously into thighs with 5×106 HCT-116 or PANC-1 cells in a 1:1 Matrigel and PBS solution. Mice are treated with IR or intravenous (IV) injection of ACPP-cRGD-MMAE (6 nmoles/day, 18 nmoles total, i.v.), tumor tissue is harvested, formalin fixed and paraffin embedded followed by staining with indicated antibodies. The primary antibody is used at a 1:250 dilution and is visualized using DAB as a chromagen with the UltraMap system.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (645 KB)
- English - EN (645 KB)
- Français - FR (645 KB)
- Deutsch - DE (645 KB)
- Norwegian - NO (645 KB)
- Español - ES (645 KB)
- Swedish - SV (645 KB)
- Italian - IT (645 KB)
- Korean - KR (645 KB)
- Portuguese - PT (645 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. [Content Brief]
[2]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87. [Content Brief]
[3]. Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1.
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 0.7595 mL | 3.7976 mL | 7.5951 mL | 18.9879 mL |
| 5 mM | 0.1519 mL | 0.7595 mL | 1.5190 mL | 3.7976 mL | |
| 10 mM | 0.0760 mL | 0.3798 mL | 0.7595 mL | 1.8988 mL | |
| 15 mM | 0.0506 mL | 0.2532 mL | 0.5063 mL | 1.2659 mL | |
| 20 mM | 0.0380 mL | 0.1899 mL | 0.3798 mL | 0.9494 mL | |
| 25 mM | 0.0304 mL | 0.1519 mL | 0.3038 mL | 0.7595 mL | |
| 30 mM | 0.0253 mL | 0.1266 mL | 0.2532 mL | 0.6329 mL | |
| DMSO | 40 mM | 0.0190 mL | 0.0949 mL | 0.1899 mL | 0.4747 mL |
| 50 mM | 0.0152 mL | 0.0760 mL | 0.1519 mL | 0.3798 mL | |
| 60 mM | 0.0127 mL | 0.0633 mL | 0.1266 mL | 0.3165 mL |
VcMMAE Related Classifications
HY-15575 Related Classifications
Powered by Bioz